Nuvation Bio Inc

자세한 내용은 Nuvation Bio Inc 회사

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

회사 정보

종목 코드 NUVB

회사 이름Nuvation Bio Inc

상장일Jul 01, 2020

CEODr. David T. Hung, M.D.

직원 수220

유형Ordinary Share

회계 연도 종료Jul 01

주소357 Tehama Street, Floor 3

도시SAN FRANCISCO

증권 거래소NYSE Consolidated

국가United States of America

우편 번호94103

전화14157543517

웹사이트https://www.nuvationbio.com/

종목 코드 NUVB

상장일Jul 01, 2020

CEODr. David T. Hung, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

--

Dr. Robert Mashal, M.D.

Independent Director

100.00K

--

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

--

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

--

Ms. Stacy Markel

Chief People Officer

10.00K

--

Mr. Philippe Sauvage

Chief Financial Officer and Principal Financial Officer

7.30K

--

Mr. Robert B. (Rob) Bazemore, Jr.

Lead Independent Director

5.00K

--

Mr. Joe Rayne

Investor Relations

--

이름

이름/직위

직위

주식 보유

변동

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

--

Dr. Robert Mashal, M.D.

Independent Director

100.00K

--

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

--

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Hung (David T)

17.72%

Fidelity Management & Research Company LLC

14.70%

Decheng Capital LLC

7.63%

BlackRock Institutional Trust Company, N.A.

4.66%

The Vanguard Group, Inc.

4.51%

Other

50.78%

주주

비율

Hung (David T)

17.72%

Fidelity Management & Research Company LLC

14.70%

Decheng Capital LLC

7.63%

BlackRock Institutional Trust Company, N.A.

4.66%

The Vanguard Group, Inc.

4.51%

Other

50.78%

주주 유형

주주

비율

Investment Advisor

30.97%

Individual Investor

19.30%

Hedge Fund

12.40%

Investment Advisor/Hedge Fund

9.48%

Venture Capital

8.02%

Research Firm

1.03%

Bank and Trust

0.20%

Pension Fund

0.17%

Private Equity

0.01%

Other

18.42%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

340

277.65M

81.60%

-29.03M

2025Q1

346

276.31M

81.30%

-31.14M

2024Q4

336

290.52M

86.58%

+4.56M

2024Q3

324

278.55M

83.07%

+36.83M

2024Q2

323

221.78M

89.68%

-2.09M

2024Q1

305

194.38M

89.06%

-41.04M

2023Q4

290

194.02M

89.00%

-35.90M

2023Q3

285

196.95M

90.37%

-25.21M

2023Q2

286

199.03M

91.34%

-20.86M

2023Q1

290

197.27M

90.57%

-23.29M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Hung (David T)

60.28M

17.72%

+500.00K

+0.84%

Jun 16, 2025

Fidelity Management & Research Company LLC

50.03M

14.7%

+5.31M

+11.88%

Mar 31, 2025

Decheng Capital LLC

25.95M

7.63%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

15.87M

4.66%

-60.61K

-0.38%

Mar 31, 2025

The Vanguard Group, Inc.

15.34M

4.51%

-334.75K

-2.14%

Mar 31, 2025

Omega Fund Management, LLC

13.07M

3.84%

--

Mar 31, 2025

Laurion Capital Management LP

9.87M

2.9%

+3.38M

+52.06%

Mar 31, 2025

Octagon Capital Advisors LP

7.90M

2.32%

-1.30M

-14.16%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.13M

1.51%

+179.41K

+3.62%

Mar 31, 2025

State Street Global Advisors (US)

4.86M

1.43%

+256.02K

+5.57%

Mar 31, 2025

2.260USD

Nuvation Bio Inc

2.260

개요

회사

금융